2nd World Congress on
COVID & COVID Mutations

Dr. Glenn Simon Tillotson worked over 35 years in healthcare with almost 30 years in pharmaceuticals (R&D and Medical Affairs). He has completed his Bachelor of Science in Microbiology and Biochemistry from Liverpool Polytechnic, Liverpool, UK (1974-1978). In 1980 he received his Master of Science in Medicine from University of Manchester Medical School, Manchester, UK. Dr. Glenn Simon Tillotson was Visiting Distinguished Scientist of Public Health Research Institute in NYC (2001). In 2005, he has finished his Ph D from Richmond University, London. He worked as Fellow of Royal Society of Medicine, London, UK (2000), American College of Chest Physicians, Chicago (2006), International Society of Chemotherapy (2008) and Infectious Disease Society of America (2010). He received Alfred Soffer Award by American College of Chest Physicians for Editorial Excellence. Dr. Glenn Simon Tillotson has experience in drug research and development including pre-clinical studies, IND, NDA, MAA and product life cycle extension (sNDA). He had memberships of various societies. In 2014 and 2015, he worked as Scientific Advisory Board- Spero Pharmaceuticals, Cambridge MA and Scientific Advisory Board- Assembly BioSciences, NYC, respectively. Currently, Dr. Glenn Simon Tillotson working as Senior Vice President of Medical Affairs in Cempra Pharmaceuticals, Chapel Hill. He has demonstrated success in range of product development, product launches and life cycle management strategies, harnessed innovative communication strategies both externally and internally, developed several medical affairs teams both internationally and nationally and shown resourcefulness in business development activities. He served as Editorial Board and Reviewer for 24 different journals from 1991 to 2014). He has written 200 papers (>150 papers on PubMed), 5 book chapters. He edited e-book on Clostridium difficile, published in September 2013 by Future Medicine, London, UK.  Given >500 lectures to National, Regional or State conferences.

Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs.

Dr Pia Forsberg is currently working as a Professor in Infectious Medicine at the Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University and a Consultant in Infectious Diseases,Linköping University and University Hospital of Linkoping.

Tick-borne diseases with special focus on the clinical manifestations , diagnostic aspects, epidemiology and immune-response.

After receiving his Ph.D. in Biochemistry and Molecular Biology at the University of Zürich, Switzerland, Prof. Linden trained in Molecular Virology at Cornell University Medical College, N.Y. He then joined the faculty at Mount Sinai School of Medicine in New York, where he used a multidisciplinary approach to understanding the molecular mechanisms and the potential applicability of site-specific genome integration by adeno-associated virus (AAV). In 2007, he moved on to set up a new research group at King’s College London. His contributions to the field include the biochemical and structural determination of the AAV Rep proteins, which orchestrate all aspects of the AAV life cycle, and the proposal of a mechanism of site-specific integration. During these studies Prof. Linden’s laboratory has demonstrated the potential of using embryonic stem cells for gaining insights into complex viral mechanisms.More recently, Prof. Linden has engaged in the field of AAV-mediated gene therapy and, in his role as the Director of the UCL Gene Therapy Consortium is responsible for clinical grade vector production and the support for further developments in UK based gene therapy efforts. In this context Prof. Linden is actively engaged in translational projects aimed at the development of therapies for a variety of diseases using AAV-based vectors.

Molecular Virology; Gene Therapy; parvoviruses; AAV; site-specific genome integration; viral DNA replication; embryonic stem cells as a model for viral mechanisms.

Amedeo Amedei in 1996 he graduated with full marks and honours in Biology at Florence University. He started his scientific career studying the role of Th1/Th2 lymphocytes in GVHD, atopic dermatitis and kidney rejection. After he examined the role of Helicobacter pylori-specific immune response in gastric diseases. In 2003 began his doctor’s degree in "Clinical and Sperimental Medicine". In 2005 he became researcher at Department of Experimental and Clinical Medicine (University of Florence), where in 2015 he was appointed Associate Professor. Recently, the Prof. Amedei has focused his scientific interests on the cancer immunology. The great quality of his international profile is documented by scientific production: 126 peer reviewed articles (3474 Citations), 6 book chapters and one patent. The Prof. Amedei is serving as an editorial board member of 56 international journals and carries out activities as scientific reviewer for international research projects of private and public entities.

Infectious diseases,General Pathology, Immunology, Immunohematology, Immunological Techniques

Maria S. Salvato received her BA at UCLA and a doctorate in Virology at UCBerkeley in 1979. She did post-doctoral studies at UCSF on RNA Processing with Dr. Christine Guthrie. 1980 she became a Sr Scientist at the MRC- Cambridge UK, under the direction of Sydney Brenner. In 1985 she joined Michael Oldstones group at the Scripps Research Foundation where she completed the first arenavirus sequence and discovered the zinc-binding gene product of the arenaviruses. From 1990-2000 she was a faculty member at the University of Wisconsin, Madison, where she developed a primate model for viral hemorrhagic fever. Dr. Salvato is currently a Professor at the Institute of Human Virology, University of Maryland Medical School. She has been active on NIH study sections, has chaired the ICTV-Arenavirus Group from 2000-2011, and has served on an Institute of Medicine panel on Smallpox.

The Salvato laboratory investigates virus-host interactions using animal models, genomic profiling, and basic molecular virology. Recent studies explored arenavirus pathogenesis using non-human primate models for Lassa fever. Lassa fever vaccine research, has resulted in two live-attenuated candidates: one (ML29) is a reassortant between Lassa virus and Mopeia virus, and the other (YF/LAS) is a recombinant between the Yellow Fever vaccine (YF17D) and the Lassa glycoprotein. The ML29 candidate is broadly cross-reactive and protects primates from Lassa fever. The YF/LAS is effective in protecting guinea pigs but not primates. Current studies explore adjuvants to DNA vaccination that require Treg suppression.